Research article |

MSF submission for the inclusion of peginterferon alfa-2a and -2b in the WHO Essential Medicines List

HIV/AIDS INTELLECTUAL PROPERTY AND TRADE TROPICAL & NEGLECTED DISEASES
HepC_statement_WHOInclusionPIEML_ENG_2013.pdf

Summary statement of the proposal for inclusion

Inclusion of the injectable formulation of peginterferon alfa-2a and -2b is proposed for the treatment of hepatitis C among adults.

The principal reasons for requesting this inclusion are as follows:

  • There is significant burden of hepatitis C disease among adults living in resource-limited settings.
     
  • The combination of interferon alfa 2a or 2b and ribavirin is the current first line and only commercially available treatment for hepatitis C disease.
     
  • Treatment of hepatitis C will be improved with wider availability of this injectable treatment.